Options Spy: Tesla 0DTE call options volume spikes
Friday was "Four Dark Days", when a large number of derivatives contracts linked to stocks, index options and futures expired, forcing traders to roll over existing positions en masse or start new ones. This time, the four Witch days coincided with a rebalancing of benchmarks such as the S&P 500, which was another catalyst for more stock trading.
SoftBank's chip design company Arm went to the United States to welcome the honeymoon market on the first day of listing, the market value exceeded 65 billion US dollars, the largest IPO in the United States this year, but also wake up the long-dormant US IPO market. The Dow Jones Industrial Average rose more than 300 points on Thursday (14th), its strongest one-day performance since early August, and its third consecutive day of gains.
On the data front, driven by higher energy and transportation costs, U.S. producer prices rose 1.6 percent in August, higher than market expectations and the second straight month of growth, but excluding volatile food and energy, core producer prices rose 2.2 percent in August, in line with market expectations.
On the political and economic front, James Bullard, a former Fed hawk and former president of the Federal Reserve Bank of St. Louis, believes that in the interest rate bitmap that is expected to be released after the Fed raises rates, officials may revise up their forecasts for the interest rate outlook because officials are concerned that the economy is still strong and inflation remains stubborn.
0DTE Options:
In the 0DTE option transaction, the ITM option was traded in large volume, and the institutional trading intention was unknown. In the technology stock, Tesla 0DTE option $TSLA 20230915 277.5 CALL$ saw a number of large buy orders.
Option buyer open position (Single leg)
Buy TOP T/O:
$EL 20260116 155.0 CALL$ $AKRO 20240119 75.0 CALL$
Buy TOP Vol:
$AZN 20231117 70.0 CALL$ $BTU 20231020 24.0 CALL$
$Estee Lauder(EL)$ Redburn: Upgraded Estee Lauder to "neutral" from "sell."
$Akero Therapeutics(AKRO)$ Evercore ISI Group: Maintained Akero Therapeutics(AKRO.US) rating to Outperform from Outperform, with price target revised to $60.00 from $50.00.
$AstraZeneca PLC(AZN)$ Astrazeneca Fasenra achieves primary endpoint in Mandara Phase 3 clinical trial.
Note: This image data is from Tiger PC. This screening is a significant buy open position for options contracts in the market. The purchase of a call option means that the trader believes that the underlying has upward momentum, and the purchase of a put option means that the trader believes that the underlying has downward momentum. These contract openings typically indicate significant activity in the underlying stock, including whether the trader is willing to accumulate a long or short option position.
Option seller open position (Single leg)
Sell TOP T/O:
$AAPL 20230922 190.0 PUT$ $LMT 20231020 460.0 PUT$
Sell TOP Vol:
$MMAT 20260116 0.5 CALL$ $CCJ 20231020 42.0 CALL$
Note: This image data is from Tiger PC. This screen is a significant sell open position for an option contract in the market. A sell of a call option means that the trader believes that the underlying trend has peaked, and a sell of a put option means that the trader believes that the underlying trend has bottomed. These contract openings typically indicate significant activity in the underlying stock, including whether the trader is willing to accumulate a long or short option position.
Options portfolio open position
Note: This image data is from Tiger PC. This screening is a significant portfolio of options contracts in the market. Portfolio opening includes a variety of underlying trends, requiring traders to further master the basic knowledge of options for analysis and judgment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Great ariticle, would you like to share it?
Great ariticle, would you like to share it?
Great ariticle, would you like to share it?
Great ariticle, would you like to share it?
Great article you want to share it
Here